1. Generics Bulletin
  2. >>Business

Mylan Ups Investment In Mapi’s Monthly Glatiramer

Puts Another $20m Into Candidate Undergoing Phase III Trials

 
• By Dave Wallace

Mylan has invested a further $20m in a monthly glatiramer acetate depot product being developed by partner Mapi for submission via the 505(b)(2) route in the US.

Calendar
Mapi and Mylan are developing a monthly glatiramer depot formulation • Source: Shutterstock

Mylan has agreed to invest a further $20m to support trials for a monthly glatiramer acetate depot product being developed by partner Mapi Pharma for the US market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.